Autoimmune liver disease
Comprehensive panel testing to diagnose common forms of autoimmune liver disease
Due to the variance in forms of autoimmune liver disease, which include autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and overlapping syndromes, patients can be misdiagnosed. Early and accurate diagnosis can lead to better treatment outcomes for patients, namely, the avoidance of end-stage liver disease and the need for liver transplantation.
Autoimmune liver disease Test menu
Autoimmune liver disease
Our panel detects and quantifies antimitochondrial antibodies using an enzyme immunoassay and smooth muscle antibodies by indirect immunofluorescence assay (IFA) with mouse stomach/kidney substrate.
Key testing
Advantages
- Screening evaluation for individuals suspected of autoimmune liver disease.
- Detects for two types of antibodies associated with AIH and one that is highly suggestive of PBC.
- Can help guide diagnosis in patients with liver disease of unknown etiology.
Highlights
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' updated ALDG2 assay helps with the evaluation of patients with suspected autoimmune liver disease. The panel also helps with the evaluation of liver disease of unknown etiology.
Primary biliary cholangitis
Primary biliary cholangitis, or PBC, is an autoimmune liver disease that can cause liver failure and death. Our suite of testing expands the options for diagnosing PBC by including testing for anti-mitochondrial antibodies (AMA) and SP100 and GP210 antibodies, as well as antinuclear antibodies using HEp-2 substrate by indirect fluorescent assay.
While the majority of PBC patients are positive for AMA antibodies, a subset is negative. Testing for SP100 and GP210 antibodies is recommended for all patients who are suspected to have PBC but test negative for AMA. These tests can be ordered individually (Mayo IDs: SP100 and GP210) or together in a PBC panel (Mayo ID: PBC2).
Key testing
- PBCPN | Primary Biliary Cholangitis Antibody Panel, Serum
- Includes testing for AMA, SP100, GP210, and HEp-2 substrate by indirect fluorescent assay for antinuclear antibodies.
- PBC2 | SP100 and GP210 Antibodies, IgG, Serum
- SP100 | SP100 Antibody, IgG, Serum
- GP210 | GP210 Antibody, IgG, Serum
Highlights
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune liver disease.